ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jan 19, 2023 10:35 JST
Source: Eisai
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
TOKYO, Jan 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai's European regional headquarters, Eisai Europe Ltd.
Israel's pharmaceutical market reached 5.3 billion USD in 2021.1 The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56%1 and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.
In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon. Eisai Israel was established in August 2021, and in January 2023, became the marketing authorization holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.
With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel as quickly as possible, and contribute to improving the benefits of patients and their families.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project
Jan 27, 2023 15:25 JST
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
Jan 27, 2023 11:46 JST
TMC Announces Changes to Executive Structure
Jan 27, 2023 10:59 JST
Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region
Jan 26, 2023 19:16 JST
Kurita Water Industries and Hitachi Launch a Co-creation to Implement Solution in Society and Build an Ecosystem for a Sustainable Society with "Zero Environmental Impact"
Jan 26, 2023 19:02 JST
Four Companies Announce Joint Feasibility Study of Large-Scale and Wide-Area Carbon Capture and Storage (CCS) Value Chain Project Using Ship Transportation
Jan 26, 2023 18:28 JST
Mitsubishi Power Receives Order for H-25 Gas Turbine for Taiwan's Chang Chun Petrochemical
Jan 26, 2023 18:22 JST
Fujitsu and Mizuho Bank embark on collaboration for sustainable management information services
Jan 26, 2023 13:44 JST
All-New eK X EV Earns Top Rating in Vehicle Safety Performance 2022 Car Assessment by JNCAP
Jan 26, 2023 09:01 JST
DOCOMO Announces World's First Technology that Utilizes Human-Augmentation Platform for Sharing Haptic Information Between People
Jan 25, 2023 17:17 JST
EEJA (TANAKA Precious Metals) to Exhibit at 37th INTERNEPCON JAPAN
Jan 25, 2023 11:00 JST
EEJA (TANAKA Precious Metals) to Exhibit at 37th INTERNEPCON JAPAN
Jan 25, 2023 11:00 JST
Hitachi Astemo, Trend Micro, and VicOne Expand Collaboration on Security Solutions for Connected Cars, Targeting 2025 Commercialization
Jan 25, 2023 09:02 JST
Honda to Make Organizational Changes (Effective April 1, 2023) to Further Accelerate Electrification Business and Realize New Value Creation
Jan 24, 2023 17:18 JST
Honda and GS Yuasa Reach Basic Agreement Toward Collaboration for a High-capacity, High-output Lithium-ion Battery
Jan 24, 2023 16:02 JST
KDDI starts commercial deployment of 5G Open vRAN sites in Japan in collaboration with Samsung Electronics and Fujitsu Limited
Jan 24, 2023 10:22 JST
Nurburgring gives green light for a comprehensive digitization measure of the world-famous Nordschleife
Jan 23, 2023 16:55 JST
NBB and JCB Enable the Acceptance of JCB Cards Through its POS & E-Commerce Merchants in The Kingdom of Bahrain
Jan 23, 2023 15:00 JST
JCB starts Red Guahan Shuttle Free Ride Campaign in Guam
Jan 23, 2023 12:00 JST
Ogier claims ninth Monte win in TOYOTA GAZOO Racing one-two
Jan 23, 2023 11:23 JST
More Latest Release >>
Related Release
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
1/27/2023 11:46:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
1/19/2023 9:07:00 AM JST
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
1/18/2023 1:28:00 PM JST
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
1/16/2023 6:56:00 PM JST
Eisai Launches Renewed Sustainability Page
1/13/2023 3:06:00 PM JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
1/11/2023 12:52:00 PM JST
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
1/9/2023 9:55:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
1/9/2023 8:40:00 PM JST
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
12/22/2022 6:07:00 PM JST
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
12/20/2022 12:01:00 PM JST
More Press release >>